Infliximab is Effective in the Treatment of Ulcerative Colitis with Dermatomyositis: A Case Report

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 Dec 28

PMID 33362394

Citations 5

Authors

Bin-Bin Huang

Li-Chun Han

Geng-Feng Liu

Xiao-Dan Lv

Guang-Li Gu

Shi-Quan Li

Lan Chen

Hui-Qin Wang

Ling-Ling Zhan

Xiao-Ping Lv

Affiliations

Soon will be listed here.

Abstract

Background: Joint, skin, oral cavity, and eye lesions are the most common extraintestinal manifestations of ulcerative colitis that can occur before or after its onset. The cases of ulcerative colitis with dermatomyositis (DM) are rare. In this study, we report a rare case of ulcerative colitis with DM that was effectively treated with infliximab.

Case Summary: The patient was a 57-year-old female with a 2-year history of DM. The patient was admitted to hospital with abdominal pain, diarrhea, and blood in stool lasting for more than 2 mo. Colonoscopy revealed multiple erosions and ulcers in the entire colon and rectum. Pathological sections showed chronic inflammatory cell infiltration, especially neutrophil infiltration, in the colonic mucosa; therefore, the patient was diagnosed with ulcerative colitis. Preparations of 5-aminosalicylic acid was added to her treatment based on the original treatment for DM, but its effect was unsatisfactory. The patient's discomfort was relieved after infliximab treatment.

Conclusion: Infliximab can improve DM in the treatment of ulcerative colitis. Specialists need to raise awareness about patients with inflammatory bowel disease who have rare extraintestinal manifestations.

Citing Articles

Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions.

Guo J, Wang W, Huang A, Mei C Med Sci Monit. 2024; 30:e944564.

PMID: 39275800 PMC: 11409827. DOI: 10.12659/MSM.944564.

Myositis as an Extraintestinal Manifestation of Ulcerative Colitis: A Case Report and Literature Review.

Nagi T, Gheit Y, Hernandez O, Suarez Z, Vallejo C, Haider M Cureus. 2023; 15(7):e42336.

PMID: 37614279 PMC: 10443962. DOI: 10.7759/cureus.42336.

Disseminated tuberculosis following negative QuantiFERON-TB gold tests during infliximab therapy: Implications for screening of hidradenitis suppurativa.

Ntiri M, Haskin A, Lowenstein E JAAD Case Rep. 2022; 29:76-79.

PMID: 36199671 PMC: 9527620. DOI: 10.1016/j.jdcr.2022.08.048.

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Elhage K, Zhao R, Nakamura M Clin Cosmet Investig Dermatol. 2022; 15:1815-1831.

PMID: 36105749 PMC: 9467686. DOI: 10.2147/CCID.S382628.

A machine learning risk model based on preoperative computed tomography scan to predict postoperative outcomes after pancreatoduodenectomy.

Capretti G, Bonifacio C, De Palma C, Nebbia M, Giannitto C, Cancian P Updates Surg. 2021; 74(1):235-243.

PMID: 34596836 DOI: 10.1007/s13304-021-01174-5.

References

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Ebert E . Review article: the gastrointestinal complications of myositis. Aliment Pharmacol Ther. 2009; 31(3):359-65. DOI: 10.1111/j.1365-2036.2009.04190.x. View

Vavricka S, Schoepfer A, Scharl M, Lakatos P, Navarini A, Rogler G . Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(8):1982-92. PMC: 4511685. DOI: 10.1097/MIB.0000000000000392. View

Zhang C, Shu W, Zhou G, Lin J, Chu F, Wu H . Anti-TNF- Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease. Mediators Inflamm. 2019; 2018:3021863. PMC: 6282128. DOI: 10.1155/2018/3021863. View

Bourikas L, Papadakis K . Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15(12):1915-24. DOI: 10.1002/ibd.20942. View

Tseng C, Chang S, Liao W, Chan Y, Tsai W, Ou T . Increased Cumulative Incidence of Dermatomyositis in Ulcerative Colitis: a Nationwide Cohort Study. Sci Rep. 2016; 6:28175. PMC: 4914943. DOI: 10.1038/srep28175. View

Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J . A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2017; 47(6):858-864. PMC: 6208161. DOI: 10.1016/j.semarthrit.2017.10.010. View

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U . Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(12):1512. DOI: 10.1093/ecco-jcc/jjx105. View

Vos A, Wildenberg M, Arijs I, Duijvestein M, Verhaar A, De Hertogh G . Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2011; 18(3):401-8. DOI: 10.1002/ibd.21818. View

10.

Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76. DOI: 10.1056/NEJMoa050516. View

11.

Nielsen O, Ainsworth M . Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013; 369(8):754-62. DOI: 10.1056/NEJMct1209614. View

12.

Gong Y, Lin Y, Zhao N, He X, Lu A, Wei W . The Th17/Treg Immune Imbalance in Ulcerative Colitis Disease in a Chinese Han Population. Mediators Inflamm. 2016; 2016:7089137. PMC: 4763012. DOI: 10.1155/2016/7089137. View

13.

Harbord M, Annese V, Vavricka S, Allez M, Barreiro-de Acosta M, Boberg K . The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2015; 10(3):239-54. PMC: 4957476. DOI: 10.1093/ecco-jcc/jjv213. View

14.

Szabo N, Lukacs S, Kulcsar I, Gunasekera W, Nagy-Toldi A, Dezso B . Association of idiopathic inflammatory myopathy and Crohn's disease. Clin Rheumatol. 2008; 28(1):99-101. DOI: 10.1007/s10067-008-1032-8. View

15.

Siegel C, Whitman C, Spiegel B, Feagan B, Sands B, Loftus Jr E . Development of an index to define overall disease severity in IBD. Gut. 2016; 67(2):244-254. DOI: 10.1136/gutjnl-2016-312648. View

16.

Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C . Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128(7):1805-11. DOI: 10.1053/j.gastro.2005.03.003. View

17.

Espinosa-Ortega F, Gomez-Martin D, Santana-de Anda K, Romo-Tena J, Villasenor-Ovies P, Alcocer-Varela J . Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets. Clin Exp Immunol. 2014; 179(3):520-8. PMC: 4337684. DOI: 10.1111/cei.12475. View

18.

Kidambi T, Schmajuk G, Gross A, Ostroff J, Terdiman J, Lee J . Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study. World J Gastroenterol. 2017; 23(26):4788-4795. PMC: 5514644. DOI: 10.3748/wjg.v23.i26.4788. View

19.

Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

20.

Zippi M, Corrado C, Pica R, Avallone E, Cassieri C, De Nitto D . Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014; 20(46):17463-7. PMC: 4265606. DOI: 10.3748/wjg.v20.i46.17463. View